683 Capital Management LLC Sells 438,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

683 Capital Management LLC cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 38.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 697,000 shares of the biopharmaceutical company’s stock after selling 438,000 shares during the quarter. TG Therapeutics makes up about 1.3% of 683 Capital Management LLC’s holdings, making the stock its 13th largest holding. 683 Capital Management LLC’s holdings in TG Therapeutics were worth $20,980,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of TGTX. Quadrant Capital Group LLC increased its position in shares of TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 975 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 371 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 1,594 shares during the period. Jones Financial Companies Lllp grew its holdings in shares of TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 1,737 shares in the last quarter. Finally, Synergy Asset Management LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $75,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $45.37 on Friday. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $7.20 billion, a price-to-earnings ratio of -453.65 and a beta of 2.14. The stock’s 50 day moving average is $38.28 and its 200-day moving average is $33.05.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Equities research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on TGTX shares. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.